Fluvastatin: Difference between revisions

Line 4:

* Major Indication: Hyperlipidemia & High Cholesterol ([[Metabolic Disorders|Hypercholesterolemia]])<br />

* Drug Class: [[HMGR]] Inhibitor or Statin

* Date of FDA Approval (Patent Expiration): 1993 (~~2000~~)<br />

* Date of FDA Approval (Patent Expiration): 1993 (2011)<br />

* ~~2009~~ Sales: $~~12.7 Billion~~ <ref></ref>

* 2000 Sales: $430 Million <ref></ref>

* Why You Should Care: Was largely replaced by [[Lipitor]]. Statins are so ubiquitous, doctors have even suggested handing them out with fast food. See: [http://www.bbc.co.uk/news/health-10955522 the article] <br />

* The following is a list of Pharmacokinetic Parameters. See: [[Pharmaceutical Drugs]] for more information

===Mechanism of Action===

~~[[Atorvastatin]]~~ is an inhibitor of [[HMG-CoA Reductase]] (HMGR), a ~~<scene name='Atorvastatin/Statin_ator/1'>~~highly regulated enzyme~~</scene>~~ responsible for the committed step in cholesterol synthesis. Atorvastatin <scene name='HMG-CoA_Reductase/Statin_ator/7'>binds HMGR</scene> via a number of polar interactions with the "cis loop" of HMGR, particularly residues Ser 684, Asp 690, Lys 691, Lys 692, and hydrogen bond interactions between Glu 559 and Asp 767 with the O5-hydroxyl of the statins. Van der Waals interactions between Leu 562, Val 683, Leu 853, Ala 856, and Leu 857 of HMGR and hydrophobic ring structures of Atorvastatin contribute to binding as well.<ref>PMID:11349148</ref> These interactions help Atorvastatin outcompete outcompete HMG-CoA, the substrate of HMGR, in binding to HMGR.<ref>PMID:7784310</ref>

Fluvastatin is an inhibitor of [[HMG-CoA Reductase]] (HMGR), a highly regulated enzyme responsible for the committed step in cholesterol synthesis. Fluvastatin outcompetes HMG-CoA, the substrate of HMGR, in binding to HMGR.<ref>PMID:7784310</ref>

===Pharmacokinetics===

{| class="wikitable" border="1" width="48%" style="text-align:center"

|-

Fluvastatin: Difference between revisions

Navigation menu

Page actions

Page actions

Personal tools

Navigation

Search

Tools

@@ Line 4: / Line 4: @@
 * Major Indication: Hyperlipidemia & High Cholesterol ([[Metabolic Disorders|Hypercholesterolemia]])<br />
 * Drug Class: [[HMGR]] Inhibitor or Statin
-* Date of FDA Approval (Patent Expiration): 1993 (2000)<br />
+* Date of FDA Approval (Patent Expiration): 1993 (2011)<br />
-* 2009 Sales: $12.7 Billion <ref></ref>
+* 2000 Sales: $430 Million <ref></ref>
 * Why You Should Care: Was largely replaced by [[Lipitor]]. Statins are so ubiquitous, doctors have even suggested handing them out with fast food. See: [http://www.bbc.co.uk/news/health-10955522 the article] <br />
 * The following is a list of Pharmacokinetic Parameters. See: [[Pharmaceutical Drugs]] for more information
 ===Mechanism of Action===
-[[Atorvastatin]] is an inhibitor of [[HMG-CoA Reductase]] (HMGR), a <scene name='Atorvastatin/Statin_ator/1'>highly regulated enzyme</scene> responsible for the committed step in cholesterol synthesis. Atorvastatin <scene name='HMG-CoA_Reductase/Statin_ator/7'>binds HMGR</scene> via a number of polar interactions with the "cis loop" of HMGR, particularly residues Ser 684, Asp 690, Lys 691, Lys 692, and hydrogen bond interactions between Glu 559 and Asp 767 with the O5-hydroxyl of the statins. Van der Waals interactions between Leu 562, Val 683, Leu 853, Ala 856, and Leu 857 of HMGR and hydrophobic ring structures of Atorvastatin contribute to binding as well.<ref>PMID:11349148</ref> These interactions help Atorvastatin outcompete outcompete HMG-CoA, the substrate of HMGR, in binding to HMGR.<ref>PMID:7784310</ref>
+Fluvastatin is an inhibitor of [[HMG-CoA Reductase]] (HMGR), a highly regulated enzyme responsible for the committed step in cholesterol synthesis. Fluvastatin outcompetes HMG-CoA, the substrate of HMGR, in binding to HMGR.<ref>PMID:7784310</ref>
 ===Pharmacokinetics===
 {| class="wikitable" border="1" width="48%" style="text-align:center"
 |-